2161 (2161) Fair Value & Analysis

Healthcare · Market cap HK$1.7B

2 2161 2161 · HK

PriceHK$2.02

Fair ValueHK$4.89

Upside+142.1%

Quality63/100

Watch 2161 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$3.58 – HK$6.32

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −15.5% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.87 – HK$3.12 · fair‑value band HK$3.58 – HK$6.32 · the HK$2.02 price screens below the HK$4.89 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2161 (2161) currently trades at HK$2.02, while our model-based Fair Value estimate is HK$4.89 — implying the stock looks roughly 142.1% undervalued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 2161 generated revenue of HK$835M at a net margin of 24.1%. Revenue grew 5.6% year over year. It earns a return on equity of 18.3%. Net debt stands at HK$274M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$835M

Revenue growth (YoY) +5.6%

Net margin 24.1%

Return on equity 18.3%

Free cash flow HK$206M FY2025

P/E ratio 8.1

More key figures

Operating margin 29.2%

EPS (TTM) HK$0.1100

Dividend yield 8.5%

EPS growth (YoY) -2.2%

Net debt HK$274M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

2161 reported revenue of HK$835M in FY2026 versus HK$406M in FY2022, a compound +19.7%/yr. Reported net income was HK$201M in FY2026, compounding +69.1%/yr from FY2022.

Revenue +19.7%/yr

FY22 HK$406M

FY23 HK$520M

FY24 HK$648M

FY25 HK$782M

FY26 HK$835M

Net income +69.1%/yr

FY22 HK$24.6M

FY23 HK$57.1M

FY24 HK$130M

FY25 HK$197M

FY26 HK$201M

Is 2161 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2161 (2161) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$4.89 versus a price of HK$2.02 — about +142% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2161?

Our model-based fair value for 2161 is HK$4.89 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.02.

What is the quality score of 2161?

2161 has a Quality Score of 63/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2161 (2161)?

2161 reported trailing-twelve-month revenue of about HK$835M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2161?

The net profit margin of 2161 is about 24.1%, meaning it keeps roughly 24.1% of revenue as net income. Based on the latest reported figures.

Does 2161 pay a dividend?

2161 currently shows a dividend yield of about 8.51% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.